Evidence map›Paper›PMID 17921226›Full record

ReviewAJNR. American journal of neuroradiology

Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders.

D J Rigotti, M Inglese, O Gonen

Open access · hybridAbstract readReview
In one paragraph

Review in AJNR. American journal of neuroradiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Emerging Role of N-Acetylaspartate in Cancer.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Subacute Changes inDiagnostics (Basel, Switzerland) · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

D J RigottiDepartment of Radiology, New York University School of Medicine, New York, NY10016, USA.
M Inglese
O Gonen
New York University · US

Funding

QUANTITATIVE MRI AND 1H-MRS IN TRAUMATIC BRAIN INJURYR01NS039135 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI LUI, YVONNE W · 2000 to 2017
$10.1M
HIGHER SPEED, FIELD &SPATIAL RESOLUTION BRAIN 3D 1H MRSR01EB001015 · NIBIB · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GONEN, ODED · 2002 to 2011
$5.8M
QUANTITATIVE MR IMAGING AND PROTON SPECTROSCOPY IN MSR37NS029029 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI GROSSMAN, ROBERT I. · 1999 to 2005
$4.2M
Quantitative MR Imaging & Proton Spectroscopy in MS.R01NS029029 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI GE, YULIN · 1991 to 2013
$3.5M
Serial Brain 3D 1H MR Spectroscopy in Multiple SclerosisR01NS050520 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GONEN, ODED · 2005 to 2009
$2.9M
Novel MRI and 1H-MRS markers in Primary Progressive MSR01NS051623 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI INGLESE, MATILDE · 2006 to 2009
$1.5M
Serial Brain 3D 1H MR Spectroscopy in Multiple Sclerosis.R56NS050520 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GONEN, ODED · 2011 to 2011
$586k
Novel MRI markers in progressive Multiple SclerosisR56NS051623 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI INGLESE, MATILDE · 2011 to 2011
$393k
NIBIB NIH HHS EB01015NIBIB NIH HHS R01 EB001015NINDS NIH HHS NS050520NINDS NIH HHS NS051623NINDS NIH HHS NS29029NINDS NIH HHS NS39135NINDS NIH HHS R01 NS029029NINDS NIH HHS R01 NS039135NINDS NIH HHS R01 NS050520NINDS NIH HHS R01 NS051623NINDS NIH HHS R37 NS029029NINDS NIH HHS R56 NS050520NINDS NIH HHS R56 NS051623
6 · The paper itself

Abstract

Proton MR spectroscopy (1H-MR spectroscopy) is a quantitative MR imaging technique often used to complement the sensitivity of conventional MR imaging with specific metabolic information. A key metabolite is the amino acid derivative N-acetylaspartate (NAA), which is almost exclusive to neurons and their processes and is, therefore, an accepted marker of their health and attenuation. Unfortunately, most 1H-MR spectroscopy studies only account for small 1- to 200-cm volumes of interest (VOI), representing less than 20% of the total brain volume. These VOIs have at least 5 additional restrictions: 1) To avoid contamination from subcutaneous and bone marrow lipids, they must be placed away from the skull, thereby missing most of the cortex. 2) They must be image-guided onto MR imaging-visible pathology, subjecting them to the implicit assumption that metabolic changes occur only there. 3) They encounter misregistration errors in serial studies. 4) The time needed to accumulate sufficient signal-intensity quality is often restrictive, and 5) they incur (unknown) T1- and T2-weighting. All these issues are avoided (at the cost of specific localization) by measuring the nonlocalized average NAA concentration over the entire brain. Indeed, whole-brain NAA quantification has been applied to several diffuse neurodegenerative diseases (where specific localization is less important than the total load of the pathology), and the results are presented in this review.

Indexed as

Magnetic Resonance SpectroscopyAspartic AcidBiomarkersBrainBrain InjuriesBrain NeoplasmsDementiaHumansMultiple SclerosisNeuronsAspartic AcidBiomarkersN-acetylaspartate

Identifiers

PMID17921226
PMCPMC8134227
OpenAlexW2121063409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.